U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C18H21N3O
Molecular Weight 295.3788
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of DIBENZEPIN

SMILES

CN(C)CCN1C2=C(C=CC=C2)N(C)C3=C(C=CC=C3)C1=O

InChI

InChIKey=QPGGEKPRGVJKQB-UHFFFAOYSA-N
InChI=1S/C18H21N3O/c1-19(2)12-13-21-17-11-7-6-10-16(17)20(3)15-9-5-4-8-14(15)18(21)22/h4-11H,12-13H2,1-3H3

HIDE SMILES / InChI

Molecular Formula C18H21N3O
Molecular Weight 295.3788
Charge 0
Count
MOL RATIO 1 MOL RATIO (average)
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description

Dibenzepin is a tricyclic antidepressant of the dibenzo-epine group. It is a selective noradrenaline uptake inhibitor, which exhibits in vitro and in vivo imipramine-like effects. It binds strongly to histamine H1 receptors in the brain and, to a lesser extent, to cholinergic receptors. The pharmacological profile of dibenzepin corresponds widely to its biochemical properties: histamine antagonism, tetrabenazine antagonism, potentiation of various noradrenergic effects and anticholinergic effects. Dibenzepin is only available in European countries for the treatment of depression.

CNS Activity

Originator

Approval Year

Targets

Primary TargetPharmacologyConditionPotency

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
NOVERIL

PubMed

Sample Use Guides

In Vivo Use Guide
In adult patients, treatment should begin with Noveril (dibenzepin) 240 mg tablets, the daily dose being given as a single dose or in 2 divided dose.
Route of Administration: Oral
In Vitro Use Guide
Dibenzepin blocked calcium current in enzymatically isolated rat ventricular myocytes with IC(50) values of 364 uM.
Substance Class Chemical
Record UNII
510SJZ1Y6L
Record Status Validated (UNII)
Record Version